Sen. Bernie Sanders (I-VT) is calling on global pharmaceutical leaders to get behind proposals laid out in a World Health Organization-led global pandemic preparedness agreement that’s nearing completion. endpts.com/sanders-presse…

Generate Bio, Isomorphic and Xaira have emerged as the frontrunners in a new wave of biotechs using AI to make drugs. It's not the first time startups have tried to upend R&D. Andrew Dunn and I ask what's different this time around in our latest Endpoints News

endpts.com/the-next-gener…

GSK says it is owed a portion of Pfizer and BioNTech’s Covid-19 vaccine sales in the latest patent suit filed against the Comirnaty partners. endpts.com/gsk-accuses-pf…

Bristol Myers outlines 'about 12' pipeline cuts as it executes major cutbacks $BMY

endpts.com/bristol-myers-…

Regeneron will pay $5 million upfront & make a $95 million equity investment in the CRISPR startup Mammoth in a new collaboration

Further deepens Regeneron's genetic medicines efforts, while outlining plans to bring gene editing beyond the liver: endpts.com/regeneron-and-…

Bristol Myers is cutting about 2,200 jobs (6% of workforce), the company says -- part of a $1.5B cost cut program announced Thursday with earnings:

endpts.com/bristol-myers-…

Roche on Wednesday morning said it has “minor exposure” from the Biosecure Act, adding that it is making strides in China’s pharma and diagnostics markets. endpts.com/roche-unruffle…

Drugmakers join lobbying push on China bill as scrutiny of WuXi continues

From Lia DeGroot and me.

endpts.com/drug-and-biote…

scoop: Optum is shutting down its virtual care business, raising questions about how UnitedHealth Group is thinking about its virtual strategy. Some employees were told that their last date will be in July.

endpts.com/optum-is-shutt…

lots of news✨ today --

FDA approves targeted treatment for most common brain tumor in kids

“We now have shown that you can develop drugs intentionally for children at the speed of biotech,” Sam Blackman said

endpts.com/fda-gives-acce…

Part 3 of our coverage of the launch of AI drug startup of Xaira — a Q&A with CEO and ex-Stanford president Marc Tessier-Lavigne, talking to Andrew Dunn + Ryan Cross the Science Boss about the company, his plans and his controversial exit from Stanford:

endpts.com/marc-tessier-l…

Last year Marc Tessier-Lavigne stepped down from his post as president of Stanford. Now he is back as CEO of Xaira Therapeutics. Andrew Dunn and I talked to him about AI, joining Xaira, the Stanford research integrity investigation and more for Endpoints News

endpts.com/marc-tessier-l…

Much more on this coming later today. In the meantime, what better time to subscribe to Endpoints News 😉

endpts.com/in-biggest-eve…

$1B+ in committed capital makes Xaira one of the biggest raises in biotech history
endpts.com/in-biggest-eve…

me reading this story: 😮😯😲

Among the head-turning details:

ex-Stanford prez Marc Tessier-Lavigne returns to biotech as CEO

investors include ARCH, Foresite, NEA, F-Prime, Sequoia, Lux

board includes Carolyn Bertozzi, ex- J&J CEO Alex Gorsky, former FDA head Scott Gottlieb
endpts.com/in-biggest-eve…

In the biggest bet on AI for drug discovery and development yet, Xaira Therapeutics has raised over $1 billion from ARCH, Foresite and others, Andrew Dunn and I exclusively report for Endpoints News.

endpts.com/in-biggest-eve…

Novartis will change CRO relationships ‘over time’ to align with Biosecure Act - endpts.com/novartis-will-…

BREAKING: With over $1 billion & a star-studded cast, a new AI bio called Xaira Therapeutics is launching with massive ambitions to remake R&D, its leaders exclusively tell Ryan Cross the Science Boss and me.

A lot to unpack in this scoop — read it only Endpoints News:
endpts.com/in-biggest-eve…

Here's were Xaira ranks among the biggest biopharma venture raises since 2010. Very little else even comes close: